{"id":"sstr2","name":"Somatostatin receptor 2","symbol":"SSTR2","route":"/targets/sstr2/","asOf":"2026-09-04","xrefs":[{"hgnc":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:11331","ensembl":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000180616","uniprot":"https://www.uniprot.org/uniprotkb/P30874/entry","alphafold-db":"https://alphafold.ebi.ac.uk/entry/P30874","chembl":"https://www.ebi.ac.uk/chembl/explore/target/CHEMBL1804","open-targets":"https://platform.opentargets.org/target/ENSG00000180616","civic":"https://civicdb.org/genes/6752/summary","oncokb":"https://www.oncokb.org/gene/SSTR2","cosmic":"https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=SSTR2","cbioportal":"https://www.cbioportal.org/results/mutations?cancer_study_list=msk_impact_2017&gene_list=SSTR2","depmap":"https://depmap.org/portal/gene/SSTR2?tab=overview","human-protein-atlas":"https://www.proteinatlas.org/ENSG00000180616-SSTR2","ncbi-gene":"https://www.ncbi.nlm.nih.gov/gene/6752","omim":"https://www.omim.org/entry/182452"}],"products":[{"id":"itm-11","name":"177Lu-edotreotide","status":"phase-3","modality":"Radioligand therapy (beta)","route":"/drugs/itm-11/"},{"id":"alphamedix","name":"212Pb-DOTAMTATE","status":"phase-2","modality":"Targeted alpha therapy (lead-212)","route":"/drugs/alphamedix/"},{"id":"ryz101","name":"Actinium-225 DOTATATE","status":"phase-3","modality":"Targeted alpha therapy","route":"/drugs/ryz101/"},{"id":"cam2029","name":"CAM2029 (octreotide subcutaneous depot)","status":"phase-3","modality":"Peptide somatostatin analogue (octreotide) in a long-acting subcutaneous depot","route":"/drugs/cam2029/"},{"id":"ga68-dotatate","name":"Gallium-68 DOTATATE (and Cu-64 DOTATATE)","status":"approved","modality":"PET radiotracer (somatostatin receptor ligand)","route":"/drugs/ga68-dotatate/"},{"id":"lutathera","name":"Lutetium-177 dotatate","status":"approved","modality":"Radioligand therapy (beta)","route":"/drugs/lutathera/"},{"id":"paltusotine","name":"Paltusotine","status":"approved","modality":"Oral non-peptide somatostatin receptor 2 agonist","route":"/drugs/paltusotine/"},{"id":"pasireotide","name":"Pasireotide","status":"approved","modality":"Multireceptor somatostatin analogue (subcutaneous or monthly depot)","route":"/drugs/pasireotide/"},{"id":"octreotide-lanreotide","name":"Somatostatin analogues (octreotide, lanreotide)","status":"approved","modality":"Peptide hormone analogue (SSTR2 agonist)","route":"/drugs/octreotide-lanreotide/"}],"trials":[{"id":"compete","name":"COMPETE","nct":"NCT03049189","phase":"3","status":"positive"},{"id":"nct03972488","name":"Study to Evaluate the Efficacy and Safety of Lutathera in Patients With Grade 2 and Grade 3 Advanced GEP-NET","nct":"NCT03972488","phase":"3","status":"active"},{"id":"spinet","name":"SPINET","nct":"NCT02683941","phase":"3","status":"mixed"},{"id":"nct00383708","name":"Lanreotide Autogel and Pegvisomant Combination Therapy in Acromegalic Patients","nct":"NCT00383708","phase":"3","status":"completed"},{"id":"netter-1","name":"NETTER-1","nct":"NCT01578239","phase":"3","status":"positive"},{"id":"nct01137682","name":"Efficacy and Safety of Pasireotide Long Acting Release (LAR) Versus Octreotide LAR or Lanreotide Autogel (ATG) in Patients With Inadequately Controlled Acromegaly","nct":"NCT01137682","phase":"3","status":"completed"},{"id":"nct00600886","name":"Safety and Efficacy of Pasireotide Long Acting Release (LAR) vs. Octreotide LAR in Patients With Active Acromegaly","nct":"NCT00600886","phase":"3","status":"completed"},{"id":"clarinet","name":"CLARINET","nct":"NCT00353496","phase":"3","status":"positive"},{"id":"nct00434148","name":"Safety and Efficacy of Different Dose Levels of Pasireotide in Patients With de Novo, Persistent or Recurrent Cushing's Disease","nct":"NCT00434148","phase":"3","status":"completed"},{"id":"promid","name":"PROMID","nct":"NCT00171873","phase":"3","status":"positive"},{"id":"nct04847505","name":"68Ga-DOTA-TATE PET/CT Imaging in NETs","nct":"NCT04847505","phase":"3"},{"id":"nct05050942","name":"A Trial to Assess Efficacy and Safety of Octreotide Subcutaneous Depot in Patients With GEP-NET","nct":"NCT05050942","phase":"3","status":"active"},{"id":"action-1","name":"ACTION-1","nct":"NCT05477576","phase":"3","status":"recruiting"},{"id":"nct07087054","name":"Carcinoid Syndrome Efficacy Study Featuring an Oral Daily Paltusotine Regimen","nct":"NCT07087054","phase":"3","status":"recruiting"},{"id":"nct05918302","name":"Efficacy and Safety of Radiotherapy Compared to Everolimus in Somatostatin Receptor Positive Neuroendocrine Tumors of the Lung and Thymus.","nct":"NCT05918302","phase":"3","status":"recruiting"},{"id":"nct06807437","name":"Lanreotide Versus Placebo Before Surgery to Prevent a Surgical Complication Called a Pancreatic Fistula","nct":"NCT06807437","phase":"3","status":"recruiting"},{"id":"nct04919226","name":"Lutetium 177Lu-Edotreotide Versus Best Standard of Care in Well-differentiated Aggressive Grade-2 and Grade-3 GastroEnteroPancreatic NeuroEndocrine Tumors (GEP-NETs) - COMPOSE","nct":"NCT04919226","phase":"3","status":"active"},{"id":"alphamedix-02","name":"ALPHAMEDIX-02","nct":"NCT05153772","phase":"2","status":"positive"},{"id":"nct04711135","name":"Study to Evaluate Safety and Dosimetry of Lutathera in Adolescent Patients With GEP-NETs and PPGLs","nct":"NCT04711135","phase":"2","status":"active"},{"id":"nct05880394","name":"Study of Dotatate Imaging in Breast Cancer","nct":"NCT05880394","phase":"2"},{"id":"nct05142696","name":"A Study of [177Lu]Lu-DOTA-TATE in Newly Diagnosed ES-SCLC Patients in Combination With Carboplatin, Etoposide and Atezolizumab","nct":"NCT05142696","phase":"1/2","status":"active"},{"id":"nct06590857","name":"Trial of 225Ac-DOTATATE (RYZ101) in Subjects With ER+, HER2-negative Unresectable or Metastatic Breast Cancer Expressing SSTRs.","nct":"NCT06590857","phase":"1/2","status":"active"}],"pathways":[],"companies":["bms","camurus","crinetics-pharmaceuticals","curium","ipsen","itm","novartis","orano-med","perspective-therapeutics","point-biopharma","radiomedix","rayzebio","recordati","sanofi"],"keyPapers":["paper-netter-2-lancet-2024"],"hotspots":[],"openQuestions":[],"assays":[],"resistance":[],"licence":"CC BY-NC 4.0, attribution to OnCo (https://onco.cc); commercial use needs a licence"}